MedTrace Logo

Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial

NCT04324463 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 6667

Last updated 2024-01-11

No results posted yet for this study

Summary

ACT is a randomized clinical trial to assess therapies to reduce the clinical progression of COVID-19.

Conditions

  • Coronavirus
  • Severe Acute Respiratory Syndrome

Interventions

DRUG

Colchicine

oral medication

DRUG

Interferon-Beta

subcutaneous injection

DRUG

Aspirin

oral medication

DRUG

Rivaroxaban

oral medication

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Population Health Research Institute

    lead OTHER

Principal Investigators

  • Richard Whitlock, MD PhD · Population Health Research Institute

  • Emilie Belley-Cote, MD PhD · Population Health Research Institute

  • John Eikelboom, MBBS MSc · Population Health Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-21
Primary Completion
2022-12-30
Completion
2022-12-30

Countries

  • Brazil
  • Canada
  • Colombia
  • Ecuador
  • Egypt
  • India
  • Nepal
  • Pakistan
  • Philippines
  • Russia
  • South Africa
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04324463 on ClinicalTrials.gov